CD4 and neoplasm: As Duhen and authors note, their findings suggest the possibility of sorting functional DP CD4+ TILs from tumor biopsy material to provide an enriched source of nonexhausted, Treg-depleted, tumor antigen–specific T cells that could be expanded ex vivo for subsequent transfer back into the patient as an adoptive immunotherapy (11, 16, 17).